3-PIPERIDIN-3-YL-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[4,3-A]AZEPINE
![]() |
- $310 - $705
- Product name: 3-PIPERIDIN-3-YL-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[4,3-A]AZEPINE
- CAS: 923164-14-1
- MF: C12H20N4
- MW: 220.31
- EINECS:
- MDL Number:MFCD08689814
- Synonyms:3-PIPERIDIN-3-YL-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[4,3-A]AZEPINE;5H-1,2,4-Triazolo[4,3-a]azepine, 6,7,8,9-tetrahydro-3-(3-piperidinyl)-
4 prices
Selected condition:
Brand
- AK Scientific
- Alichem
- Crysdot
- TRC
Package
- 250mg
- 1g
- ManufacturerAK Scientific
- Product numberV9164
- Product description3-Piperidin-3-yl-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine
- Packaging1g
- Price$705
- Updated2021-12-16
- Buy
- ManufacturerAlichem
- Product number923164141
- Product description3-(Piperidin-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
- Packaging1g
- Price$431.64
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11013008
- Product description3-(Piperidin-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine 95+%
- Packaging1g
- Price$535
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB450625
- Product description3-piperidin-3-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
- Packaging250mg
- Price$310
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | V9164 | 3-Piperidin-3-yl-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine | 1g | $705 | 2021-12-16 | Buy |
Alichem | 923164141 | 3-(Piperidin-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine | 1g | $431.64 | 2021-12-16 | Buy |
Crysdot | CD11013008 | 3-(Piperidin-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine 95+% | 1g | $535 | 2021-12-16 | Buy |
TRC | B450625 | 3-piperidin-3-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine | 250mg | $310 | 2021-12-16 | Buy |
Properties
storage temp. :2-8°C
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|